By Malcolm Lee Kitchen III | Margin Of The Law

American healthcare is one of the most expensive systems in the world, and it is also one of the most unequal. The country spends $5.7 trillion on health this year alone, roughly one-fifth of everything the economy produces. Yet more than 27 million Americans have no insurance. Drugs that cost a fraction of their U.S. price in Canada or Germany sit behind pharmacy counters that millions of people cannot afford to approach.

This is not a mystery without causes. Four forces are driving the state of American healthcare right now: drug pricing and the politics around it, the fragility of health coverage under premium pressure, the arrival of artificial intelligence in clinical practice, and the weakening of the public health infrastructure that protects all of us from disease outbreaks that it causes.

Here is what is actually happening in each of those areas, based on federal data and current research.

Drug Prices: A Historic Policy Shift Is Underway

Americans pay more for prescription drugs than any other wealthy nation. That gap has persisted for decades because drug manufacturers set their own launch prices, and the government has historically had no legal authority to negotiate those prices.

That changed. The Inflation Reduction Act gave Medicare the power to negotiate drug prices directly with pharmaceutical companies for the first time. The first ten negotiated prices took effect January 1, 2026, saving Medicare enrollees an estimated $1.5 billion in a single year. The second round covers fifteen more drugs representing $42.5 billion in annual Medicare spending, with negotiated prices taking effect in 2028. Those fifteen drugs treat conditions including type 2 diabetes, HIV, asthma, and several cancers.

This is real, documented progress. It is also limited. The negotiation authority currently applies only to Medicare, not to commercial insurance. Patients with private plans still face the old system.

At the same time, Congress passed the first meaningful reform of Pharmacy Benefit Managers, the middlemen who negotiate on behalf of insurers. The Consolidated Appropriations Act of 2026 bans PBM fees tied to drug prices under Medicare Part D and requires rebates to pass through to patients at the pharmacy counter. It is a start, but experts argue the reforms stop well short of the structural overhaul the PBM industry needs.

The administration also floated a proposal called TrumpRx, which would allow some patients to purchase medications at government-negotiated rates directly, bypassing insurance. Critics note that patients who need the most expensive drugs, those with complex cancer or rare disease diagnoses, depend on insurance coverage, not list prices, and the proposal would offer them little relief.

The bottom line: drug pricing is changing, but slowly, and primarily for people on Medicare.

Health Insurance: Millions Are Losing Ground

27.1 million Americans were uninsured in 2024. That number had already risen by 670,000 from the prior year, and 2026 is shaping up to be worse.

The main reason is the expiration of enhanced premium tax credits that had been subsidizing ACA marketplace coverage since 2021. Those subsidies allowed middle-income Americans to buy coverage they otherwise could not afford. Without them, premiums for 22 million people increased an average of 114 percent. The Congressional Budget Office projects 3.8 million people will lose coverage annually as a result.

Marketplace premiums rose 20 to 26 percent across the board in 2026. Some states saw higher spikes. Young adults, who face the highest uninsured rates at 14.1 percent, and Hispanic Americans, at 24.6 percent uninsured, are absorbing much of the impact.

The legislative package known as the Big Beautiful Bill contains changes to Medicaid, the program that covers one in five Americans. Work requirements, modified eligibility rules, and per-capita funding limits are among the provisions the American Medical Association has flagged as coverage risks. Medicaid is not just a coverage program. When rural hospitals lose Medicaid patients, they frequently close, which removes all care from communities that have no other options.

On the hospital side, consolidation continues. Financially distressed sellers drove 43 percent of 2025 hospital mergers, and analysts expect more deals in 2026. Research consistently shows that consolidation raises prices and, in rural areas, often leads to service closures. The economics of the current system push hospitals toward merging and patients toward having fewer choices.

AI in Medicine: Fast, Promising, and Partly Unregulated

The FDA had authorized more than 1,250 AI-enabled medical devices for clinical use as of late 2025. A year earlier, that number was around 950. The growth is accelerating.

Most of these devices are imaging tools. Radiology accounts for 76 percent of all authorized AI medical products. AI systems can already review thousands of X-rays, CT scans, and pathology slides in the time it takes a radiologist to read a handful. More importantly, well-designed systems detect early signs of cancer, cardiovascular disease, and neurological conditions before symptoms appear. Earlier detection means earlier treatment, which affects both survival rates and costs.

But there is a major regulatory development here that deserves attention. On January 6, 2026, the FDA published guidance reducing its pre-market review of lower-risk digital health tools, including some AI-enabled software. Previously, the agency focused 90 to 95 percent of its AI oversight attention on what happens before a product reaches patients. The new strategy shifts toward post-market monitoring: products get to patients sooner, and the agency watches what happens afterward.

This approach has genuine benefits, primarily speed. It also carries risk. AI systems that perform well in controlled development environments sometimes underperform in diverse clinical populations. Post-market surveillance needs to scale with the number of products reaching patients, and whether the FDA has the resources to do that given current budget pressures is an open question.

Telehealth got a meaningful win. Congress extended federal telehealth authorizations through 2027, and the DEA permanently authorized telemedicine prescribing for buprenorphine, the most effective medication for opioid use disorder. Patients can now begin treatment without an in-person visit. For rural patients who might live 60 or 90 minutes from the nearest prescriber, that change is significant.

Public Health: The Weakest It Has Been in Decades

The most underreported story in American healthcare in 2026 is what has happened to the public health infrastructure that most people take for granted.

The CDC’s FY 2026 budget is $4.243 billion. That sounds large until you compare it to FY 2024, when the agency had $9.2 billion. That is a 53 percent cut in two years. On top of the budget reduction, HHS terminated 444 CDC grants totaling $5.78 billion in unliquidated obligations as of May 2026, and clawed back more than $12 billion in COVID-era grants that were approved to strengthen state and local public health systems.

What does a public health system do? It watches for disease outbreaks. It investigates cluster cases. It maintains the laboratory networks that identify novel pathogens. It trains the local health officers who respond when something unusual appears. When that system is depleted, the warning time between a novel outbreak and a community crisis gets shorter.

NIH is investing in pandemic preparedness through a new research network focused on developing vaccines and monoclonal antibodies for high-priority pathogens, with approximately $100 million per year committed. That is valuable long-term work. It does not replace the surveillance and response capacity that budget cuts have reduced.

The Workforce Crisis No One Is Talking About Enough

The United States will face a physician shortage of up to 86,000 by 2036. A more recent HRSA projection puts the total across all specialties at 187,130 by 2037. Nurses are also in short supply. National nursing supply in 2026 covers only about 92 percent of demand, with licensed practical nurses facing a 20 percent gap.

The driver is demographic. The number of healthcare workers over 60 doubled between 2000 and 2020. As Baby Boomers retire from clinical practice, they take decades of experience with them. The pipeline of new graduates is not large enough to replace them, particularly in rural and underserved areas where the shortage is already most severe.

Shortages affect care quality and cost. Patients wait longer for appointments. Overextended providers make more errors under pressure. Rural hospitals with insufficient staff divert emergency cases to distant facilities. And patients with less access see providers later in the course of disease, when treatment is more complex and expensive.

The Opioid Crisis: Real Progress, Real Fragility

There is actual good news here. Opioid overdose deaths fell from 79,358 in 2023 to 54,045 in 2024, a drop driven largely by declines in fentanyl-involved deaths. Preliminary data for 2025 suggests a further 13.9 percent annual decline in total overdose deaths.

Progress is real. The underlying problem is not solved. Among adults who needed opioid use disorder treatment in 2022, only 25 percent received the recommended medications. Barriers including cost, stigma, provider availability, and geography keep effective treatment out of reach for the majority of people who need it.

SAMHSA, the federal agency responsible for behavioral health and addiction programs, faces a potential $1.07 billion budget cut for FY 2026 and has already experienced significant staffing reductions, including staff supporting the 988 Suicide and Crisis Lifeline. Cutting the behavioral health agency’s capacity at the same time the telehealth prescribing expansion creates new treatment pathways is not a coherent policy approach.

The Bigger Picture

These four stories connect. A patient who loses ACA coverage skips a screening. An AI tool that could have flagged that cancer early was never used. A public health department running on a depleted budget misses the initial cluster signal of an outbreak. A rural resident cannot reach a prescribing provider even with telemedicine because there are no providers in driving distance to begin with.

American healthcare in 2026 is not one crisis but several, happening simultaneously, in a system that has limited margin for error. The decisions being made this year in Congress, on premium subsidies, Medicaid financing, CDC funding, and AI regulation, will produce measurable outcomes for years.

Those outcomes will show up in coverage statistics, in overdose numbers, in outbreak response times, and in the basic experience of whether you can afford to see a doctor when you need one.

Sources: Centers for Medicare and Medicaid Services, Kaiser Family Foundation, Peterson-KFF Health System Tracker, Center on Budget and Policy Priorities, American Medical Association, FDA, NIH, CDC, Trust for America’s Health, Kaufman Hall, HRSA, Medicus HCS.

Margin of the Law publishes constitutional analysis, civic research, and legal education for people who want to understand the system they actually live in. Read the Full Constitutional Analysis Library at marginofthelaw.com.

© 2026 – MK3 Law Group
For republication or citation, please credit this article with link attribution to marginofthelaw.com.